RecruitingNot ApplicableNCT06717412

Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy

Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy: A Multicenter, Prospective, Randomized, Double-blind, Non-inferiority Clinical Trial

Sponsor

Wang Yusheng

Enrollment

146 participants

Start Date

Nov 29, 2024

Study Type

INTERVENTIONAL

Conditions

Retinopathy of Prematurity (ROP)

Summary

Evaluating the Optimal Effective Dose and Safety of Conbercept in Treating Retinopathy of Prematurity (ROP)

Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Conbercept for people with retinopathy of prematurity (rop). The study is currently recruiting participants at 3 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.